(lp0
S'Why Puma Biotechnology Inc. Got Hammered Today Motley Fool - Mar 2, 2017 The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.Puma Biotech shares plummet 26% after Roche reports positive results for late ... - MarketWatch'
p1
aS'Puma Biotechnology Inc  Moves Higher on Volume Spike for March 17 Equities.com - 17 hours ago Puma Biotechnology Inc  traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a&nbsp;...Analysts Set Puma Biotechnology Inc  Price Target at $70.50 - The Cerbat GemZacks Rank on Puma Biotechnology Inc  based on Estimated Earnings - Energy Index'
p2
aS"Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc , Puma ... Smarter Analyst - Mar 2, 2017 Puma Biotechnology Inc  shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial, which explores usefulness of Perjeta in adjuvant breast cancer ...Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA ... - Benzinga"
p3
aS'Why Puma Biotechnology Inc. Sold Lower Today Motley Fool - Oct 19, 2016 Puma Biotechnology is looking to raise $150 million selling shares, which will dilute current shareholders. Another $22.5 million of shares could also be sold within 30 days if the underwriters want the extra shares.Puma Biotechnology Inc  Swamped by New Shares - Scibility MediaPuma Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire '
p4
aS"Why Puma Biotechnology Inc Roared Higher Today Motley Fool - Sep 20, 2016 Puma Biotechnology  was up as much as much as 15% today after announcing that the Food and Drug Administration accepted the company's marketing application for its breast cancer drug neratinib, although it's given up some of that gain&nbsp;...JP Morgan Comments on Puma Biotechnology Inc  Following NDA Acceptance - Smarter AnalystPuma Biotechnology Announces US FDA Acceptance of New Drug Application for ... - Business Wire "
p5
aS'Why Puma Biotechnology, Inc. Stock Soared 65.1% in July Motley Fool - Aug 4, 2016 What: Shares of Puma Biotechnology, Inc.  a clinical-stage biopharmaceutical company developing a cancer therapy, shot up 65.1% in July, according to data from S&amp;P Global Market Intelligence.'
p6
aS'Puma Biotechnology Inc  Soars 11.86% on March 13 Equities.com - Mar 13, 2017 Puma Biotechnology Inc  had a good day on the market for Monday March 13 as shares jumped 11.86% to close at $44.80. About 1.88 million shares traded hands on 13,031 trades for the day, compared with an average daily volume of 972,852 shares&nbsp;...In focus: Puma Biotechnology, Inc.  Trading Patterns - Post AnalystThe State Street Corp Acquires 1032915 Shares of Puma Biotechnology Inc  - Petro Global News 24'
p7
aS'PUMA BIOTECHNOLOGY, INC.  Files An 8-K Other Events Market Exclusive - Mar 1, 2017 Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer.Puma Biotechnology Announces Publication of Abstracts on Neratinib for the ... - Business Wire '
p8
aS"Puma Biotechnology  Q4 Earnings: What's in the Cards? Yahoo Finance - Feb 27, 2017 Puma Biotechnology, Inc. PBYI is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.How Often Does Puma Biotechnology, Inc.  Miss Earnings Estimates? - Post Analyst"
p9
aS'Why Did Puma Biotechnology Dilute Shareholders? Motley Fool - Nov 29, 2016 Kristine Harjes: One recent secondary offering that was announced in the healthcare world was that of Puma Biotechnology. On Oct. 18, after the closing bell, they announced that they wanted to raise $150 million, and potentially another $22.5 million ...'
p10
a.